Wells Fargo’s Evelo Biosciences, Inc. Common Stock EVLO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q4 | – | Sell |
-52
| Closed | -$204 | – | 7846 |
|
|
2023
Q3 | $204 | Buy |
52
+31
| +148% | +$212 | ﹤0.01% | 6583 |
|
|
2023
Q2 | $68 | Buy |
21
+1
| +5% | +$3 | ﹤0.01% | 6969 |
|
|
2023
Q1 | $73 | Hold |
20
| – | – | ﹤0.01% | 7013 |
|
|
2022
Q4 | $628 | Buy |
20
+1
| +5% | +$40 | ﹤0.01% | 6321 |
|
|
2022
Q3 | $1K | Buy |
19
+10
| +111% | +$457 | ﹤0.01% | 6541 |
|
|
2022
Q2 | $0 | Sell |
9
-83
| -90% | -$3.85K | ﹤0.01% | 7825 |
|
|
2022
Q1 | $6K | Sell |
92
-542
| -85% | -$45.1K | ﹤0.01% | 6446 |
|
|
2021
Q4 | $76K | Buy |
634
+632
| +31,600% | +$107K | ﹤0.01% | 5772 |
|
|
2021
Q3 | $0 | Hold |
2
| – | – | ﹤0.01% | 7756 |
|
|
2021
Q2 | $1K | Sell |
2
-2,501
| -100% | -$631K | ﹤0.01% | 6793 |
|
|
2021
Q1 | $535K | Buy |
2,503
+399
| +19% | +$110K | ﹤0.01% | 4650 |
|
|
2020
Q4 | $508K | Buy |
2,104
+280
| +15% | +$34.6K | ﹤0.01% | 4509 |
|
|
2020
Q3 | $192K | Sell |
1,824
-10
| -0.5% | -$911 | ﹤0.01% | 4980 |
|
|
2020
Q2 | $180K | Buy |
1,834
+1,287
| +235% | +$113K | ﹤0.01% | 4964 |
|
|
2020
Q1 | $41K | Sell |
547
-756
| -58% | -$72K | ﹤0.01% | 5412 |
|
|
2019
Q4 | $105K | Sell |
1,303
-120
| -8% | -$13.4K | ﹤0.01% | 5277 |
|
|
2019
Q3 | $173K | Buy |
1,423
+189
| +15% | +$26K | ﹤0.01% | 5055 |
|
|
2019
Q2 | $221K | Buy |
1,234
+676
| +121% | +$109K | ﹤0.01% | 4923 |
|
|
2019
Q1 | $89K | Buy |
558
+3
| +0.5% | +$594 | ﹤0.01% | 5170 |
|
|
2018
Q4 | $144K | Buy |
555
+514
| +1,254% | +$103K | ﹤0.01% | 5101 |
|
|
2018
Q3 | $10K | Buy |
41
+8
| +24% | +$2.09K | ﹤0.01% | 5998 |
|
|
2018
Q2 | $8K | Buy |
+33
| New | +$9.62K | ﹤0.01% | 6016 |
|
Other funds holding EVLO
Wells Fargo's EVLO Position: Q4 2023 in Review
Wells Fargo sold out of Evelo Biosciences, Inc. Common Stock (EVLO) in Q4 2023, closing a stake of 52 shares — an estimated $204 sold.
Wells Fargo first reported a position in EVLO in Q2 2018 and held it in 22 quarters. The position peaked at $535K in Q1 2021. 2 funds tracked by Wall St. Rank hold EVLO as of Q4 2023.
- Wells Fargo reported no remaining Evelo Biosciences, Inc. Common Stock position as of Q4 2023 after selling out during the quarter.
- Wells Fargo sold 52 Evelo Biosciences, Inc. Common Stock shares in Q4 2023, an estimated $204.
- Wells Fargo first reported a position in Evelo Biosciences, Inc. Common Stock in Q2 2018 and held it in 22 quarters.
- Wells Fargo's Evelo Biosciences, Inc. Common Stock position peaked at $535K in Q1 2021.
- 2 funds tracked by Wall St. Rank held Evelo Biosciences, Inc. Common Stock as of Q4 2023.
Based on Wells Fargo's 13F filing for Q4 2023, filed 9 Feb 2024.